Suppr超能文献

作为蛋白酶体抑制剂的肽α-酮酰胺衍生物的合成及生物活性

Synthesis and Biological Activity of Peptide α-Ketoamide Derivatives as Proteasome Inhibitors.

作者信息

Pacifico Salvatore, Ferretti Valeria, Albanese Valentina, Fantinati Anna, Gallerani Eleonora, Nicoli Francesco, Gavioli Riccardo, Zamberlan Francesco, Preti Delia, Marastoni Mauro

机构信息

Department of Chemical and Pharmaceutical Sciences, University of Ferrara, Via Luigi Borsari 46, 44121 Ferrara, Italy.

School of Chemistry, University of Nottingham, University Park, NG7 2RD, United Kingdom.

出版信息

ACS Med Chem Lett. 2019 Jun 6;10(7):1086-1092. doi: 10.1021/acsmedchemlett.9b00233. eCollection 2019 Jul 11.

Abstract

Proteasome activity affects cell cycle progression as well as the immune response, and it is largely recognized as an attractive pharmacological target for potential therapies against several diseases. Herein we present the synthesis of a series of pseudodi/tripeptides bearing at the C-terminal position different α-ketoamide moieties as pharmacophoric units for the interaction with the catalytic threonine residue that sustains the proteolytic action of the proteasome. Among these, we identified the 1-naphthyl derivative as a potent and selective inhibitor of the β5 subunit of the 20S proteasome, exhibiting nanomolar potency in vitro (β5 IC = 7 nM, β1 IC = 60 μM, β2 IC > 100 μM). Furthermore, it significantly inhibited proliferation and induced apoptosis of the human colorectal carcinoma cell line HCT116.

摘要

蛋白酶体活性影响细胞周期进程以及免疫反应,并且它在很大程度上被认为是针对几种疾病的潜在治疗方法的一个有吸引力的药理学靶点。在此,我们展示了一系列在C端带有不同α-酮酰胺部分的假二肽/三肽的合成,这些α-酮酰胺部分作为药效基团单元与维持蛋白酶体蛋白水解作用的催化苏氨酸残基相互作用。其中,我们确定1-萘基衍生物是20S蛋白酶体β5亚基的一种强效且选择性抑制剂,在体外表现出纳摩尔级别的效力(β5 IC = 7 nM,β1 IC = 60 μM,β2 IC > 100 μM)。此外,它显著抑制人结肠癌细胞系HCT116的增殖并诱导其凋亡。

相似文献

1
Synthesis and Biological Activity of Peptide α-Ketoamide Derivatives as Proteasome Inhibitors.
ACS Med Chem Lett. 2019 Jun 6;10(7):1086-1092. doi: 10.1021/acsmedchemlett.9b00233. eCollection 2019 Jul 11.
4
Discovery of novel non-covalent inhibitors selective to the β5-subunit of the human 20S proteasome.
Eur J Med Chem. 2015 Jun 15;98:61-8. doi: 10.1016/j.ejmech.2015.05.023. Epub 2015 May 16.
5
Naphthoquinone amino acid derivatives, synthesis and biological activity as proteasome inhibitors.
J Enzyme Inhib Med Chem. 2017 Dec;32(1):865-877. doi: 10.1080/14756366.2017.1334649.
6
Phenoxypropanolamine derivatives as selective inhibitors of the 20S proteasome β1 and β5 subunits.
Bioorg Med Chem Lett. 2017 Dec 1;27(23):5172-5178. doi: 10.1016/j.bmcl.2017.10.055. Epub 2017 Oct 23.
7
Terminal functionalized thiourea-containing dipeptides as multidrug-resistance reversers that target 20S proteasome and cell proliferation.
Eur J Med Chem. 2017 Jan 27;126:259-269. doi: 10.1016/j.ejmech.2016.11.024. Epub 2016 Nov 11.
8
Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
BMC Cancer. 2016 Mar 24;16:247. doi: 10.1186/s12885-016-2285-2.
10
Synthesis and biological evaluation of curcumin derivatives modified with α-amino boronic acid as proteasome inhibitors.
Bioorg Med Chem Lett. 2018 Aug 1;28(14):2459-2464. doi: 10.1016/j.bmcl.2018.06.004. Epub 2018 Jun 2.

引用本文的文献

1
Covalent-reversible peptide-based protease inhibitors. Design, synthesis, and clinical success stories.
Amino Acids. 2023 Dec;55(12):1775-1800. doi: 10.1007/s00726-023-03286-1. Epub 2023 Jun 17.
2
Direct oxidation of -ynylsulfonamides into -sulfonyloxoacetamides with DMSO as a nucleophilic oxidant.
RSC Adv. 2021 Dec 20;11(63):40243-40252. doi: 10.1039/d1ra04816c. eCollection 2021 Dec 13.
3
A new class of α-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities.
Eur J Med Chem. 2021 Apr 5;215:113267. doi: 10.1016/j.ejmech.2021.113267. Epub 2021 Feb 10.

本文引用的文献

1
Next-generation proteasome inhibitors for cancer therapy.
Transl Res. 2018 Aug;198:1-16. doi: 10.1016/j.trsl.2018.03.002. Epub 2018 Mar 26.
2
Naphthoquinone amino acid derivatives, synthesis and biological activity as proteasome inhibitors.
J Enzyme Inhib Med Chem. 2017 Dec;32(1):865-877. doi: 10.1080/14756366.2017.1334649.
3
Second Generation Proteasome Inhibitors in Multiple Myeloma.
Anticancer Agents Med Chem. 2017;17(7):920-926. doi: 10.2174/1871520616666160902101622.
4
Activation of Chymotrypsin-Like Activity of the Proteasome during Ischemia Induces Myocardial Dysfunction and Death.
PLoS One. 2016 Aug 16;11(8):e0161068. doi: 10.1371/journal.pone.0161068. eCollection 2016.
5
Recent Developments in General Methodologies for the Synthesis of α-Ketoamides.
Chem Rev. 2016 Mar 9;116(5):3241-305. doi: 10.1021/acs.chemrev.5b00443. Epub 2016 Feb 16.
6
Ixazomib: First Global Approval.
Drugs. 2016 Mar;76(3):405-11. doi: 10.1007/s40265-016-0548-5.
7
Studies of C-terminal naphthoquinone dipeptides as 20S proteasome inhibitors.
J Enzyme Inhib Med Chem. 2016;31(3):456-63. doi: 10.3109/14756366.2015.1037749. Epub 2015 May 5.
8
α-Keto phenylamides as P1'-extended proteasome inhibitors.
ChemMedChem. 2014 Nov;9(11):2557-64. doi: 10.1002/cmdc.201402244. Epub 2014 Aug 1.
9
Peptide-based proteasome inhibitors in anticancer drug design.
Med Res Rev. 2014 Sep;34(5):1001-69. doi: 10.1002/med.21312. Epub 2014 Mar 1.
10
The emerging role of carfilzomib combination therapy in the management of multiple myeloma.
Expert Rev Hematol. 2014 Apr;7(2):265-90. doi: 10.1586/17474086.2014.873699. Epub 2014 Feb 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验